[go: up one dir, main page]

WO2006105538A3 - Methodes et compositions de traitement de pathologies afferentes a l'il-21 - Google Patents

Methodes et compositions de traitement de pathologies afferentes a l'il-21 Download PDF

Info

Publication number
WO2006105538A3
WO2006105538A3 PCT/US2006/012749 US2006012749W WO2006105538A3 WO 2006105538 A3 WO2006105538 A3 WO 2006105538A3 US 2006012749 W US2006012749 W US 2006012749W WO 2006105538 A3 WO2006105538 A3 WO 2006105538A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
treating
compositions
related pathologies
ige
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/012749
Other languages
English (en)
Other versions
WO2006105538A2 (fr
Inventor
Keying Ma
Xiao-Yu Song
Donald E Grisworld
Xiaozhou Shang
Li Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of WO2006105538A2 publication Critical patent/WO2006105538A2/fr
Anticipated expiration legal-status Critical
Publication of WO2006105538A3 publication Critical patent/WO2006105538A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des méthodes de traitement d'au moins un état ou une pathologie lié à l'IL-21, qui incluent des procédés, des dispositifs et des compositions thérapeutiques. Ladite pathologie implique l'augmentation de la production d'IgE ou la commutation isotopique d'IgE.
PCT/US2006/012749 2005-03-31 2006-03-31 Methodes et compositions de traitement de pathologies afferentes a l'il-21 Ceased WO2006105538A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66678405P 2005-03-31 2005-03-31
US60/666,784 2005-03-31

Publications (2)

Publication Number Publication Date
WO2006105538A2 WO2006105538A2 (fr) 2006-10-05
WO2006105538A3 true WO2006105538A3 (fr) 2009-04-23

Family

ID=37054232

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/012749 Ceased WO2006105538A2 (fr) 2005-03-31 2006-03-31 Methodes et compositions de traitement de pathologies afferentes a l'il-21

Country Status (1)

Country Link
WO (1) WO2006105538A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1963369T3 (pl) 2005-11-28 2013-10-31 Zymogenetics Inc Antagoniści IL-21
WO2009047360A1 (fr) * 2007-10-11 2009-04-16 Novo Nordisk A/S Anticorps il-21
ES2584237T3 (es) 2007-12-07 2016-09-26 Zymogenetics, Inc. Anticuerpos monoclonales anti-IL-21 humana
US7635707B1 (en) 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
PT3636274T (pt) 2011-01-18 2024-10-17 Bioniz Therapeutics Inc Composições para modular a atividade das citocinas gama-c
CA2915882C (fr) 2013-06-27 2022-12-06 Monash University Proteines de liaison il-21 et leurs utilisations
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
PT3104853T (pt) 2014-02-10 2020-01-14 Respivant Sciences Gmbh Tratamento com estabilizadores de mastócitos para distúrbios sistémicos
CA2938996A1 (fr) 2014-02-10 2015-08-13 Patara Pharma, LLC Methodes de traitement de maladies pulmonaires au moyen de stabilisateurs de mastocyte
US10940212B2 (en) 2014-12-19 2021-03-09 Monash University IL-21 agonist antibodies and methods of treatment using same
EP3331522A1 (fr) 2015-08-07 2018-06-13 Patara Pharma LLC Méthodes de traitement de troubles liés aux mastocytes par des stabilisateurs de mastocytes
US10265296B2 (en) 2015-08-07 2019-04-23 Respivant Sciences Gmbh Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
ES2884357T3 (es) 2015-10-09 2021-12-10 Bioniz Llc Modulación de la actividad de las citocinas gamma-c
JP2019528320A (ja) 2016-08-31 2019-10-10 レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ 特発性肺線維症による慢性咳の治療のためのクロモリン組成物
EP3522983A4 (fr) 2016-10-07 2020-06-03 Respivant Sciences GmbH Compositions à base de cromolyne pour le traitement d'une fibrose pulmonaire
WO2020227019A1 (fr) 2019-05-03 2020-11-12 Bioniz, Llc Modulation des effets de la signalisation de la cytokine gamma-c pour le traitement de l'alopécie et de troubles associés à l'alopécie

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAVEN ET AL.: "rHull-21 Enhances IgE Production in Human PBMC and Purified Tonsilar B Cellls Stimulated with IL-4 and alphaCD40 in a Cell Number, IL Concentration, and Proliferation Dependent Manner.", FASEB JOURNAL, vol. 18, no. 4-5, 2004, pages A1125 *
OZAKI ET AL.: "A Critical Role for IL-21 in Regulating Immunoglobulin Production.", SCIENCE., vol. 298, November 2002 (2002-11-01), pages 1630 - 1634 *
SHANG ET AL.: "IL-2 but not IFN-g production in a mouse model of allergy.", FASEB JOURNAL., vol. 19, no. 4, March 2005 (2005-03-01), pages A939 *
SUTO ET AL.: "Interleukin 21 prevents antigen-induced IgE production by inhibiting germ line Ce ranscription of IL-4-stimulated B cells.", BLOOD., vol. 100, no. 13, December 2002 (2002-12-01), pages 4565 - 4573 *
WOOD ET AL.: "IL-21 efects on human IgE production in response to IL-4 or IL-13.", CELLULAR IMMUNOLOGY., vol. 231, 2004, pages 133 - 145 *

Also Published As

Publication number Publication date
WO2006105538A2 (fr) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2005091853A3 (fr) Procedes et compositions pour traiter des pathologies associees a l'il-13
WO2006003388A8 (fr) Compositions et procedes pour le traitement de troubles inflammatoires
WO2008070692A8 (fr) Composés chimiques et leurs utilisations
WO2008115469A3 (fr) Rôle de la signalisation par hérisson dans l'athérosclérose et les maladies cardiovasculaires
WO2009023509A3 (fr) Combinaisons thérapeutiques utiles pour traiter les maladies liées au cftr
WO2006124748A3 (fr) Composes polycycliques et procedes pour les utiliser
WO2007007173A3 (fr) Nouveaux anticorps anti-madcam
PL1960600T3 (pl) Produkt bibułkowy traktowany kompozycją substancji dodatkowych i sposób jego wytwarzania
WO2009129246A3 (fr) Compositions et leurs procédés de préparation et d'utilisation
WO2006096490A8 (fr) Compositions d'anticorps anti-madcam
WO2006105538A3 (fr) Methodes et compositions de traitement de pathologies afferentes a l'il-21
WO2007022506A3 (fr) Méthodes et préparations pour le traitement d'une maladie neurologique
WO2007022529A3 (fr) Méthode pour traiter des maladies inflammatoires
IL184524A0 (en) Substituted pyrazolo-pyridines, compositions containing them, method for the production thereof, and their use
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
WO2008046581A3 (fr) Composés tétrahydropyrrolopyrazine substitués et leur utilisation dans des médicaments
WO2006127900A3 (fr) Tl1a dans le traitement de maladie
EP1908749A4 (fr) Procede de fabrication d'isocyanate, isocyanate fabrique selon ce procede, et utilisation de cet isocyanate
WO2006136357A3 (fr) Modifications cristallines de la pyraclostrobine
WO2008066630A3 (fr) Procédés de reprogrammation de cellules somatiques adultes, et leurs utilisations
WO2008027600A3 (fr) Compositions d'imatinib
WO2005044200A3 (fr) Procedes et compositions pour traiter des pathologies associees a la mcp-1
IL176420A0 (en) Process for the manufacture of 2,3-dichloropyridine
WO2007144057A3 (fr) Carbone antimicrobien
WO2009115252A3 (fr) Pyrazolamides substitués et leur utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 06749378

Country of ref document: EP

Kind code of ref document: A2